Chanice Henry | 08/08/2017
Experts have urged that legislation on early access programs needs to be tightened to protect the seriously ill Through expanded early access programs (EAPs), terminally- ill patients that fit certain criteria will be allowed access to unauthorized drugs outside of a clinical trial.These programs aim to give dying patients ethical and controlled strategic access to potentially life- saving medicines before they gain approval. However, the lack of clarity and harmonization of regional regul...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
DigIT Pharma 2026 | AI Commercial, Medical & Patient Care
September 9 - 10, 2026
Berlin, Germany
Register Now |
View Agenda |
Learn More
Pharmaceutical Launch Excellence Summit US
September 30 - October 1 2026
Hyatt Regency Boston Harbor, Boston, US
Register Now |
View Agenda |
Learn More